LC-MS/MS

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Retrieved on: 
Wednesday, March 20, 2024
Zealand Pharma, Plasma, Rat, LC-MS/MS, Short bowel syndrome, Half-life, Inflammation, Patient, Tablet, Teduglutide, POC, OPKO Health, Injection, Entera, Pharmaceutical industry

The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.

Key Points: 
  • The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.
  • Currently, the only approved GLP-2 agonist, which is marketed under the name Gattex® (teduglutide), requires daily sub-cutaneous injections.
  • Entera and OPKO completed a proof of concept (PoC) single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment.
  • This data is consistent with previously reported PK data relating to OPKO’s GLP-2 peptide’s long acting profile, which had initially been developed as a weekly subcutaneous injection.

Allumiqs and Prolytix form strategic partnership to accelerate drug discovery and development

Retrieved on: 
Wednesday, March 13, 2024
Partnership, GMP, 2005 in television, Research, Investment, News, LC-MS/MS, NS, Fine chemical

HALIFAX, NS and ESSEX JUNCTION, Vt., March 13, 2024 /PRNewswire/ -- Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines. Together the partners empower customers with bioanalytical solutions to advance drug candidates from the early R&D phases through to lot release.

Key Points: 
  • HALIFAX, NS and ESSEX JUNCTION, Vt., March 13, 2024 /PRNewswire/ -- Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines.
  • This strategic collaboration comes after several successful joint customer engagements, leveraging Allumiqs' expertise in multiomics and LC-MS/MS solutions and Prolytix's complementary large- molecule drug product lifecycle management.
  • Collectively the partners offer cohesive solutions that optimize efficiency and accelerate advancements in the drug development pipeline.
  • Now in partnership with Prolytix we can take all of our customers further in the drug development process with connected solutions from early R&D to lot release.

Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway

Retrieved on: 
Wednesday, February 28, 2024
LC-MS/MS, Blood, Marketing, FDA, News, Trial of the century, DSR, Contract research organization, Classification, Intelligence, Partnership, Medical device

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research , a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company’s FDA 510(k) clinical study plan.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research , a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company’s FDA 510(k) clinical study plan.
  • The fingerprint sweat specimen will be screened using INBS’ Intelligent Fingerprinting Drug Screening System comprising the Intelligent Fingerprinting Drug Screening Cartridge and DSR-Plus fluorescence reader and compared to the LC-MS/MS results.
  • The start of the clinical study plan marks an exciting milestone for the Company as it advances on its 510(k) pathway.
  • Harry Simeonidis, President and CEO at Intelligent Bio Solutions, commented, “We are pleased to share news of our partnership with Cliantha and progress on our 510(k) journey.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application

Retrieved on: 
Monday, September 18, 2023
LC-MS/MS, Rat, University, Partnership, CSE, Cerebrospinal fluid, Liquid Tension Experiment 3, The 20/20 Experience – 2 of 2, Serum, Anxiety, Pons, Prefrontal cortex, FSE, Research, Cerebellum, CSF, Experiment, Chronic pain, Pharmacology, Olfactory bulb, Pharmaceutical industry, Medical imaging, Vaccine, Brain, CBD

The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats.

Key Points: 
  • The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats.
  • The primary objectives of this study include:
    Objective 1: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain.
  • This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain (Experiments 1 and 2).
  • Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain.

Metabolon Announces Three Oral Presentations and Two Poster Presentations at the 2023 Metabolomics Society Annual Conference

Retrieved on: 
Tuesday, June 13, 2023
LC-MS/MS, Cannabinoid, Oxysterol, Molecule, QC, ECS, Nociception, ISO, Complementarity, Research, Inflammation, Appetite, PQC, Locomotion, Plasma, CLIA, Publication, Publishing, Sphingolipid, QA, Area studies, Medicine, What They Always Tell Us, Quality control, Knowledge, Memory, Medical device, Metabolomics, Metabolon, Diabetes

MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.

Key Points: 
  • MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.
  • "We are honored to present at the Metabolomics Society annual conference.
  • The presentation reports on one of the most deeply phenotyped cohort studies to date: the Qatar Metabolomics Study of Diabetes.
  • In the past year, Metabolon has launched a wide range of new targeted metabolomics panels that provide absolute quantification for important research areas.

Metabolon Announces Three Oral Presentations and Two Poster Presentations at the 2023 Metabolomics Society Annual Conference

Retrieved on: 
Tuesday, June 13, 2023
LC-MS/MS, Cannabinoid, Oxysterol, Molecule, QC, ECS, Nociception, ISO, Complementarity, Research, Inflammation, Appetite, PQC, Locomotion, Plasma, CLIA, Publication, Publishing, Sphingolipid, QA, Area studies, Medicine, What They Always Tell Us, Quality control, Knowledge, Memory, Medical device, Metabolomics, Metabolon, Diabetes

MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.

Key Points: 
  • MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.
  • "We are honored to present at the Metabolomics Society annual conference.
  • The presentation reports on one of the most deeply phenotyped cohort studies to date: the Qatar Metabolomics Study of Diabetes.
  • In the past year, Metabolon has launched a wide range of new targeted metabolomics panels that provide absolute quantification for important research areas.

Eurofins Environment Testing Wastewater Surveillance Program can play a Vital Role in Monitoring Initiatives to Identify Illicit Narcotics and Opioid Usage

Retrieved on: 
Wednesday, June 7, 2023
Mental Health, Health Technology, Public Policy, Government, Other Natural Resources, Biometrics, Other Health, Biotechnology, State, Local, Health, Natural Resources, LC-MS/MS, Prevalence, Narcotic, Methamphetamine, PFAS, Face, Metal, Tic disorder, EST, Doctor of Philosophy, College of Engineering (KNUST), Dioxin, Cocaine, National Institute on Drug Abuse, Fentanyl, Drug

The webinar will demonstrate how valuable a tool wastewater surveillance is in comprehending the prevalence and dynamics of substance abuse disorders within communities.

Key Points: 
  • The webinar will demonstrate how valuable a tool wastewater surveillance is in comprehending the prevalence and dynamics of substance abuse disorders within communities.
  • Obtaining accurate and actionable data is vital for effective coordination, strategy development, and community preparedness in the face of the opioid crisis.
  • Wastewater surveillance offers a unique opportunity to gather unbiased and accurate data on narcotics consumption at community level.
  • Co-presenters for this webinar will be Adam Gushgari, Wastewater National Business Development Manager, Eurofins Environment Testing US and Thep Phomsopha, Consultant Scientist, Eurofins Environment Testing US.

Intelligent Bio Solutions Plans to Add Fentanyl Testing as it Further Enhances its Fingerprint-Based Drug Screening Solution

Retrieved on: 
Tuesday, May 16, 2023
LC-MS/MS, Methamphetamine, Urine, Mass spectrometry, Fentanyl, Chromatography, Heroin, CDC, Death, Cocaine, Tandem mass spectrometry, Cannabis, Tranquilizer, Intelligence, Drug

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced plans to add the potent synthetic opioid drug, fentanyl, and fentanyl-adulterated street drugs, to the panel of substances detected by its lab-based confirmation testing using fingertip sweat collected by its proprietary Intelligent Fingerprinting Drug Screening System.

Key Points: 
  • The Company is combatting this healthcare crisis by expanding the capabilities of its lab-based confirmation testing service to detect fentanyl and its related analogues in samples collected by its fingerprint-based drug testing system.
  • “By seeking to add fentanyl and other fentanyl-adulterated street drugs to our fingerprint-based lab-based confirmation drug testing panel, we are furthering our commitment to equipping workplaces to better combat the opioid issue.
  • We believe making drug testing for fentanyl non-invasive, quick, and hygienic is an important step towards addressing this crisis,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.
  • Fingerprint testing provides a quick and dignified approach that is much more convenient than traditional urine or saliva drug testing methods.

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

Retrieved on: 
Friday, April 14, 2023
Chewels, US Foods, Neuropharmacology, Dermatitis, Atopic dermatitis, Doctor of Philosophy, Nicotine gum, Incidence, Acquisition, Patient, DMPK, API, Opioid overdose, Disease, Maintenance, Substance dependence, Nicotine, Research, USD, CBG, CDC, CGMP, Addiction, Smoking, Cannabidiol, Skin, Safety, British Columbia Centre for Disease Control, Opioid use disorder, Psoriasis, Translational medicine, European, Immune system, Vitiligo, LC-MS/MS, Opioid, Fatal, ASX, QPS, Food, Pharmaceutical industry, MD, Toxicology, CBD, Cannabigerol, Eurofins Scientific

Over the years, QPS has adopted additional services, including Neuropharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.

Key Points: 
  • Over the years, QPS has adopted additional services, including Neuropharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.
  • QPS is currently drafting pre-investigational new drug (pre-IND) submissions for both the European Union’s European Medicines Agency (‘EMA’) and the US Food and Drug Administration (‘FDA’) for the CannQuit™ and ReneCann™ Products.
  • CEO and Managing Director, Mr Joel Latham said; “QPS is a perfect fit for us to develop these products across the globe.
  • Data collected by Eurofins on the quality and stability of the products will be key components of future regulatory packages.